Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | INT230-6 |
| Trade Name | |
| Synonyms | INT 230-6|INT-230-6 |
| Drug Descriptions |
INT230-6 is a therapy comprised of cisplatin and vinblastine plus a cell penetration excipient, which leads to improved uptake of the drug into cancer cells, potentially resulting in tumor regression as well as indirect antitumor effects (Cancer Res 2015;75(15 Suppl):Abstract nr 4295, PMID: 31646070). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C136428 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| INT230-6 | INT230-6 | 0 | 4 |
| INT230-6 + Pembrolizumab | INT230-6 Pembrolizumab | 0 | 0 |
| INT230-6 + unspecified PD-1 antibody | INT230-6 unspecified PD-1 antibody | 0 | 1 |